【参考文献】
[1] BOUMA BN，MARX PF，MOSNIER LO，et al．Thrombinactable fibrinolysisi inhibitor.（TAFI plasma procarboxypeptidase B.procaroxypeptidaseR.procaroxypeptidaseU）［J］.Thromb Res，2001，101（5）：329354.
[2] FRRE C，MORANGE PE，SAUT N，et al：Quantification of thrombin activatable fibrinolysis inhibitor（TAFI）gene polymorphis effect on plasma levels TAFI of measured with assays insensitive to isofromdependent artiffact［J］．J Thromb Haemost，2005，94：373379.
[3] RIKA WATANABE，HIDEO WADA，YASUYUKI WATNANBE，et al：Activity and antigen levels of thrombinactivatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation［J］．Thromb Res，2001，104（1）：16.
[4] SAKHROV DA，PLOW EF，RIJKEN DC．On the mechanim of the antifibrinolytic activity of plasma procarboxypeptidase B［J］．J Biol Chem，1997，272：1447714482.
[5] ANTOVIC JP，SCHULMAN S，AN SS，et al．Dose an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A．hemophilia B and von Willebrand disease［J］．Clin Invest，2004，64（8）：745752.
[6] MＯSNIER LO，VON DER BORNE PAK，MEAJERS JCM，et al．Plasma TAFIlevels influence the clot lysiss time in healthy individuals in the presence of an intact intrinsic pathway of coagulation［J］．Thromb Haemost，1998，80（6）：829835.
[7] 谢爽，王鸿利，王学锋，等．冠心病患者血浆凝血酶激活的纤溶抑制物的检测及临床意义［J］．现代检验医学杂志，2004，1（19）：4243.
[8] MEIJERS JC，OUDI JK，MOSNIER LO，et al．Reduced activity of TAFI （thrombin activatable fibrinolysis inhibitor）in accte promyelocytic leukaemia ［J］．Br J Haematol，2000，108（3）：518523.
[9] ZHANG X，ZHOU H，WANG J，et a1．Arsenic trioxide，retinoic acid and Arac regulation the expression of annexin II on the surface of API cells，a novel coreceptor for plasminogen/tissue plasminogen activator［J］． Thromb Res，2002，106（1）：6370.
[10] OUDIJK EJ，NIEUWENHUIS HK，BOS R，et a1．Elastase mediated firinolysis in acute promyeloc
上一页 [1] [2] [3] [4] [5] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 临床医学论文 >> 正文